Advancing Therapeutics, Improving Lives

Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need.

Headquartered in Foster City, California, the company has expanded rapidly over the past two decades, with annual revenues now exceeding $4 billion, operations spanning three continents (North America, Europe and Australia) and a staff of more than 3,000 employees.

Gilead’s primary areas of focus include: antivirals (such as HIV/AIDS and chronic hepatitis), cardiovascular conditions (such as pulmonary arterial hypertension and resistant hypertension) and respiratory diseases (such as influenza and cystic fibrosis).

Our growing pipeline includes novel investigational medications for resistant hypertension, cystic fibrosis, HIV and hepatitis.

To begin learning more about Gilead Sciences, view Gilead-at-a-Glance.